Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the ...

Patients who had positive ctDNA tests after surgery were almost twice as likely to be alive at 3 years if they received ...

Natera (NTRA) commented on recent updates by the NCCN on circulating tumor DNA molecular residual disease testing in the Clinical Practice ...

Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...

SaponiQx, a leader in next-generation saponin-based adjuvant discovery and a subsidiary of Agenus Inc., today announced the ...

Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Allied Physicians Group, New York's largest independent pediatric care provider with over 38 offices, and Adjuvant.Health, ...

In the first randomized trial of its kind, researchers found that adding chemoradiation to adjuvant chemotherapy did not ...